Gene Therapy in CNS Disorder Market

Gene therapy in CNS disorder sales will rise through 2036, driven by in vivo gene therapy at 63.5% of the gene type in 2026. The market was valued at USD 13.96 billion in 2025 and is expected to be worth USD 248.39 billion by 2036, creating an incremental opportunity of USD 230.38 billion.